Date receipt dossier
Company / Sponsor
Transgene
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Metastatic adenocarcinoma of the Breast
Therapeutic approach
Immunotherapy
Genetic modification
Muc-1 and Interleukine 2 (IL-2)
Method of transfer of nucleic acid of interest
Attenuated Vaccinia Virus (Copenhagen Strain)
Administered biological material
Recombinant Attenuated Vaccinia Virus
Route of administration
Intramuscular
Locations in Belgium
Universitair Ziekenhuis Gent
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
TG1031.02